Hypha Labs (FUNI) 10-K 13 Jan 25 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Sep. 30, 2024	Jan. 13, 2025	Mar. 31, 2024
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--09-30
Entity File Number	000-54239
Entity Registrant Name	Hypha Labs, Inc.
Entity Central Index Key	0001502966
Entity Tax Identification Number	27-3601979
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5940 S. Rainbow Boulevard
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89118
City Area Code	(702)
Local Phone Number	527-2060
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 2,051,031
Entity Common Stock, Shares Outstanding		126,546,825
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	5525
Auditor Name	Fruci & Associates II, PLLC
Auditor Location	Spokane, Washington

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Current assets:
Cash	$ 91,166	$ 271,006
Note receivable
Other current assets	289,024	8,570
Deferred offering costs	30,000
Assets held for sale - current		486,222
Total current assets	410,190	765,798
Fixed assets, net	26,609
Right-of-use asset	57,006
Assets held for sale – long term		643,666
Total non-current assets	83,615	643,666
Total Assets	493,805	1,409,464
Current liabilities:
Accounts payable	86,348	122,094
Current maturities of notes payable		565,000
Lease liabilities - current	36,428
Liabilities held for sale - current		368,655
Total current liabilities	1,393,660	3,121,814
Non-current liabilities:
Lease liabilities – long term	26,838
Liabilities held for sale – long term		159,156
Total non-current liabilities	26,838	159,156
Total Liabilities	1,420,498	3,280,970
Commitments and contingent liabilities
Series B convertible preferred stock, $0.001 par value, 1,500,000 shares authorized; 333,600 shares issued and outstanding as of September 30, 2024 and 2023	333,600	333,600
Stockholders’ Deficit:
Common stock, $0.001 par value, 250,000,000 shares authorized; 123,046,825 and 87,096,820 shares issued and outstanding as of September 30, 2024 and 2023, respectively	123,046	87,097
Additional paid-in capital	19,163,039	17,468,746
Accumulated deficit	(20,547,426)	(19,761,997)
Total Stockholders’ Deficit	(1,260,293)	(2,205,106)
Total Liabilities and Stockholders’ Deficit	493,805	1,409,464
Series A Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	1,048	1,048
Series C Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value
Nonrelated Party [Member]
Current liabilities:
Accrued expenses	166,726	328,491
Current maturities of convertible notes payable	1,078,235	1,385,932
Related Party [Member]
Current liabilities:
Accrued expenses	25,923	12,390
Current maturities of convertible notes payable		$ 339,252

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Sep. 30, 2023
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	70,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	123,046,825	87,096,820
Common stock, shares outstanding	123,046,825	87,096,820
Series B Convertible Preferred Stock [Member]
Temporary equity, par value	$ 0.001	$ 0.001
Temporary equity, shares authorized	1,500,000	1,500,000
Temporary equity, shares issued	333,600	333,600
Temporary equity, shares outstanding	333,600	333,600
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	1,047,942	1,047,942
Preferred stock, shares outstanding	1,047,942	1,047,942
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000	1,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenues
Cost of sales
Gross profit
Operating expenses:
General and administrative	943,691	103,298
Professional fees	883,336	334,090
Total operating expenses	1,827,027	437,388
Operating loss	(1,827,027)	(437,388)
Other income (expense):
Interest expense	(201,769)	(364,267)
Other income (expense)	13,896	(55,000)
Recovery of previously written off receivables	66,000	175,000
Loss on extinguishment of debt	(956,494)
Gain on sale of subsidiary assets	1,548,998
Total other income (expense)	470,631	(244,267)
Net loss from continuing operations before income taxes	(1,356,396)	(681,655)
Income tax expense	(14,189)
Net loss from continuing operations	(1,370,585)	(681,655)
Net income (loss) from discontinued operations	585,156	928,429
Net income (loss)	$ (785,429)	$ 246,774
Net loss per share from continuing operations - basic	$ (0.01)	$ (0.01)
Net loss per share from continuing operations - fully diluted	(0.01)	(0.01)
Net income per share from discontinued operations - basic	0.01	0.01
Net income per share from discontinued operations - fully diluted	0.01	0.01
Net loss per share basic	(0.01)	0
Net loss per share fully diluted	$ (0.01)	$ 0
Weighted average number of common shares outstanding - basic	101,348,643	83,925,450
Weighted average number of common shares outstanding - fully diluted	101,348,643	83,925,450

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Stock Payable [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series B Convertible Preferred Stock [Member]	Total
Balance at Sep. 30, 2022	$ 333,600	$ 1,048	$ 1	$ 75,147	$ 71,745	$ 17,117,958	$ (20,008,771)		$ (2,742,872)
Balance, shares at Sep. 30, 2022	333,600		1,000
Balance, shares at Sep. 30, 2022		1,047,942	1,000	75,146,820
Repurchase of Series C Preferred shares			$ (1)			(99)			(100)
Repurchase of Series C Preferred shares, shares			(1,000)
Common stock issued for settlement of stock payable				$ 7,150	(71,745)	64,595
Common stock issued for settlement of stock payable, shares				7,150,000
Common stock issued for compensation				$ 4,800		29,880			34,680
Common stock issued for compensation, shares				4,800,000
Warrants issued for debt financing costs						93,938			93,938
Stock-based compensation						24,474			24,474
Forgiveness of accrued director compensation						138,000			138,000
Net income (loss)							246,774		246,774
Balance at Sep. 30, 2023	$ 333,600	$ 1,048		$ 87,097		17,468,746	(19,761,997)		(2,205,106)
Balance, shares at Sep. 30, 2023	333,600							333,600
Balance, shares at Sep. 30, 2023		1,047,942		87,096,820
Common stock issued for settlement of stock payable				$ 40,000
Common stock issued for settlement of stock payable, shares				4,000,000
Forgiveness of accrued director compensation						956,494			956,494
Net income (loss)							(785,429)		(785,429)
Shares issued for conversion of notes payable				$ 4,000		36,000			40,000
Shares issued for conversion of notes payable, shares				4,000,000
Stock-based compensation				$ 31,949		701,799			733,748
Stock-based compensation, shares				31,950,005
Balance at Sep. 30, 2024	$ 333,600	$ 1,048		$ 123,046		$ 19,163,039	$ (20,547,426)		$ (1,260,293)
Balance, shares at Sep. 30, 2024	333,600							333,600
Balance, shares at Sep. 30, 2024		1,047,942		123,046,825

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net loss from continuing operations	$ (1,370,585)	$ (681,655)
Adjustments to reconcile net loss to net cash used in operating activities:
Recovery of previously written off receivables		(175,000)
Depreciation expense	1,046
Gain on sale of subsidiary assets	(1,548,998)
Stock-based compensation	733,748	59,154
Amortization of debt discounts	43,050	135,655
Impairment of fixed assets		55,000
Amortization of right-of-use asset	17,569
Loss on debt extinguishment	956,494
Decrease (increase) in assets:
Other current assets	(60,454)	4,169
Increase (decrease) in liabilities:
Accounts payable	(30,321)	(78,465)
Accrued expenses	(136,224)	108,694
Accrued expenses – related parties	13,533	(42,421)
Lease liability	(11,309)
Net cash (used in) operating activities from continuing operations	(1,392,451)	(614,869)
Net cash provided by operating activities from discontinued operations	358,576	727,394
Net cash provided by (used in) operating activities	(1,033,875)	112,525
Cash flows from investing activities
Purchase of fixed assets	(27,655)
Proceeds from sale of subsidiary net assets	2,173,439
Proceeds from sale of collateralized assets		275,000
Net cash (used) in investing activities from continuing operations	2,145,784	275,000
Net cash (used) in investing activities from discontinued operations		(11,667)
Net cash (used) in investing activities	2,145,784	263,333
Cash flows from financing activities
Repayments of notes payable	(595,965)	(100,000)
Repayments on convertible notes	(650,000)
Payments of deferred offering costs	(30,000)
Repurchase of Series C Preferred stock		(100)
Net cash provided by (used in) financing activities	(1,275,965)	(100,100)
Net cash used in financing activities from discontinued operations	(15,784)	(60,920)
Net cash provided by (used in) financing activities	(1,291,749)	(161,020)
Net increase (decrease) in cash	(179,840)	214,838
Cash - beginning	271,006	56,168
Cash - ending	91,166	271,006
Supplemental disclosures:
Interest paid	266,533	227,691
Income taxes paid
Non-cash investing and financing activities:
Addition of accounts payable and accrued interest into note payable	30,965
Common stock issued for conversion of note payable	40,000
Initial right-of-use asset valuation	74,575
Common stock issued for settlement of stock payable		71,745
Transfer of completed assets		6,076
Warrants issued for debt financing		93,938
Common stock issued for settlement of related party accrued compensation		$ 138,000

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (785,429)	$ 246,774

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Sep. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	12 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Nature of Business and Significant Accounting Policies	Nature of Business and Significant Accounting Policies Nature of Business Hypha Labs, Inc. (formerly Digipath, Inc.) was incorporated in Nevada on October 5, 2010. Until February 20, 2024, Hypha Labs, Inc. and its subsidiaries (“Hypha,” the “Company,” “we,” “our” or “us”) was a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supported the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission was to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients knew exactly what was in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Hypha Labs had been operating a cannabis-testing lab in Nevada since 2015. On February 20, 2024, we completed the sale of the net assets of our subsidiary Digipath Labs, Inc. (“Digipath Labs”). As of that date we were no longer in business as a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, which supported the cannabis industry’s best practices for reliable testing, cannabis education and training. Effective March 12, 2024, the Company amended Article 1 of its Articles of Incorporation to change its name from Digipath, Inc. to Hypha Labs, Inc. Hypha Products, Inc., a wholly owned subsidiary of the Company, was formed on April 18, 2024. Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2024: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Hypha Labs, Inc.(formerly Digipath, Inc.) (1) Nevada Parent Hypha Products, Inc. Nevada Subsidiary Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc. (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Hypha Labs, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Hypha” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers were within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for a fair presentation of the information contained therein. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $ 0 154,179 Assets held for sale – current Notes Receivable Notes receivable are reported in our consolidated balance sheets at the outstanding principal balance, plus costs incurred to originate the loans, net of any unamortized premiums or discounts on purchased loans. We use the effective interest rate method to recognize finance income, which produces a constant periodic rate of return on the investment. Unearned income, discounts and premiums are amortized to finance income in our consolidated statements of operations using the effective interest rate method. Interest receivable related to the unpaid principal is recorded together with the outstanding balance in our consolidated balance sheets. Upon the prepayment of a note receivable, any prepayment penalties and unamortized loan origination, closing and commitment fees are recorded as part of finance income in our consolidated statements of operations. Notes receivable are periodically evaluated for collectability based on past credit history with note holders and their current financial condition. The Company had an allowance for credit losses of $ 670,000 720,000 Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Schedule of Estimated Useful Lives of Property, Plant and Equipment Software 3 Office equipment 5 Furniture and fixtures 5 Lab equipment 7 Leasehold improvements Term of lease Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations. As of September 30, 2024, all fixed assets balances are classified as Assets held for sale – long term Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. Our intellectual property is comprised of indefinite-lived brand names acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. Revenue Recognition The Company recognizes revenue in accordance with ASC 606 - Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue was primarily generated through our subsidiary, Digipath Labs, which recognized revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests, basis. Revenue from the performance of those services was recognized upon completion of the tests, at which time test results were delivered to the customer, provided collectability of the fee is reasonably assured. We typically required payment within thirty days of the delivery of results. During the years ended September 30, 2024 and 2023, all revenues are classified as part of Net income from discontinued operations Discontinued Operations On April 20, 2023, the Company and Digipath Labs entered into an Asset Purchase Agreement (the “Purchase Agreement”) with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 Assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities of discontinued operations in the Consolidated Balance Sheets as of September 30, 2024 and 2023. The results of discontinued operations are aggregated and presented separately in the Consolidated Statements of Operations as net income from discontinued operations for the years ended September 30, 2024 and 2023. The cash flows of the discontinued operations are reflected as cash flows of discontinued operations within the Company’s Consolidated Statements of Cash Flows for the years ended September 30, 2024 and 2023. Amounts presented in discontinued operations have been derived from our consolidated financial statements and accounting records using the historical basis of assets, liabilities, results of operations, and cash flows of Digipath Labs. The discontinued operations exclude general corporate allocations. Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $ 22,205 4,444 Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2024 and 2023, potential dilutive securities of 104,490,131 83,125,488 8,120,000 15,387,050 13,579,710 Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07 Segment Reporting ( Topic 280 Improvements to Reportable Segment Disclosures, In December 2023, the FASB issued ASU 2023-09 Income Taxes ( Topic 740 Improvements to Income Tax Disclosures,

Going Concern

Going Concern	12 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying consolidated financial statements, the Company has incurred recurring losses from operations resulting in an accumulated deficit of $ 20,547,426 The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 3 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2024 and 2023, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2024 Level 1 Level 2 Level 3 Liabilities Notes payable $ - $ - $ - Convertible notes payable, net of discounts of $ 43,051 - - 1,078,235 Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2023 Level 1 Level 2 Level 3 Liabilities Notes payable $ - $ 565,000 $ - Convertible notes payable, net of discounts of $ 84,767 - - 1,725,184 Convertible notes payable - - 1,725,184 The fair value of our intellectual properties is deemed to approximate book value, and are considered Level 3 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the years ended September 30, 2024 or 2023.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 – Related Party Transactions During the years ended September 30, 2024 and 2023 the Company incurred compensation expense of $ 60,000 60,000 During the years ended September 30, 2024 and 2023 the Company incurred fees of $ 24,000 34,000 138,000 10,000 As of September 30, 2024, the Company has accrued a total of $ 5,923 During the year ended September 30, 2024, the Company granted 6,000,000 112,200 3,400,000 1,400,000 24,820 9,860

Note Receivable

Note Receivable	12 Months Ended
	Sep. 30, 2024
Receivables [Abstract]
Note Receivable	Note 5 – Note Receivable On various dates between December 28, 2018 and June 13, 2019, we loaned Northwest Analytical Labs, Inc. a total of $ 95,000 10 On December 8, 2022, the Company entered into an Asset Purchase Agreement with Invictus Wealth Group (“Invictus”), whereby the Company agreed to sell certain collateralized equipment to Invictus for a total purchase price of $ 900,000 275,000 625,000 December 31, 2023 10 100,000 425,000 275,000 100,000 425,000 December 31, 2025 50,000 100,000 125,000 216,780 74,000

Fixed Assets

Fixed Assets	12 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 6 – Fixed Assets Fixed assets consist of the following at September 30, 2024 and 2023: Schedule of Fixed Assets 2024 2023 As of September 30, September 30, 2024 2023 Lab equipment $ 27,655 $ - Less: accumulated depreciation (1,046 ) - Total $ 26,609 $ - During the year ended September 30, 2023, the Company recorded impairment expense in the amount of $ 55,000

Notes Payable

Notes Payable	12 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Notes Payable	Note 7 – Notes Payable Notes payable consists of the following at September 30, 2024 and 2023, respectively: Schedule of Notes Payable September 30, September 30, On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 125,000 $ - $ 565,000 Total notes payable - 565,000 Less: current maturities - (565,000 ) Notes payable $ - $ - The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 36,614 79,800 Notes payable – discontinued operations On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five December 26, 2024 $ - $ 80,428

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 8 – Convertible Notes Payable Related party convertible notes payable consist of the following at September 30, 2024 and 2023, respectively: Schedule of Related Party Convertible Notes Payable September 30, September 30, 2024 2023 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 4,550,000 43,788 As a result of the shares issued upon the extension agreement, the lender now holds more the 5% of the total outstanding common shares, and is therefore considered a related party. On February 27, 2024, the Company repaid the note and related accrued interest in full. $ - $ 350,000 Total related party convertible notes payable - 350,000 Less: unamortized debt discounts - (10,748 ) Total convertible debt - 339,252 Less: current maturities - - Related party convertible notes payable $ - $ 339,252 Convertible notes payable consist of the following at September 30, 2024 and 2023, respectively: Schedule of Convertible Notes Payable September 30, September 30, 2024 2023 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $ 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 1,950,000 20,968 - 150,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 August 10, 2022 0.03 90,000 3,000,000 0.03 355,469 98,188 February 11, 2024 4,621,105 32,166 355,469 355,469 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 August 10, 2022 0.03 February 11, 2024 4,550,000 31,671 40,000 February 11, 2025 0.01 474,539 310,000 350,000 On October 1, 2022, the Company entered into a senior secured convertible note that carries an 8 February 11, 2024 362,765 0.01 4,715,945 30,102 362,765 362,765 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 August 10, 2022 0.03 - 150,000 Total convertible notes payable 1,078,235 1,418,234 Less: unamortized debt discounts - (32,302 ) Total convertible debt 1,078,235 1,385,932 Less: current maturities (1,078,235 ) (1,385,932 ) Convertible notes payable $ - $ - The Company recorded debt amortization expense attributed to the previously recorded debt discount in the amounts of $ 43,050 135,655 0 All of the convertible notes limit the maximum number of shares that can be owned by each note holder as a result of the conversions to common stock to 4.99 The Company recorded interest expense pursuant to the stated interest rates on the convertible notes in the amount of $ 89,603 148,812 The Company recognized interest expense for the years ended September 30, 2024 and 2023, respectively, as follows: Schedule of Interest Expense September 30, September 30, Interest on notes payable $ 36,614 $ 79,800 Amortization of debt discounts 43,050 135,655 Interest on convertible notes 89,603 148,812 Total interest expense $ 169,267 $ 364,267

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders’ Equity	Note 9 – Stockholders’ Equity Preferred Stock The Company is authorized to issue 70,000,000 0.001 6,000,000 1,500,000 1,000 2,499,000 1,047,942 333,600 1,000 Series A Preferred The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 1,047,942 5,239,710 No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice. Additional terms of the Series A Preferred include the following: ● The shares of Series A Preferred are entitled to dividends when, as and if declared by the Board as to the shares of the common stock of the Company into which such Series A Preferred may then be converted, subject to the 4.99 ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, the shares of Series A Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100 ● The Series A Preferred plus all declared but unpaid dividends thereon automatically will be converted into common stock, at the then applicable conversion rate, upon the affirmative vote of the holders of a majority of the outstanding shares of Series A Preferred. ● Each share of Series A Preferred will carry a number of votes equal to the number of shares of common stock into which such Series A Preferred may then be converted, subject to the 4.99 ● Consent of the holders of the outstanding Series A Preferred is required in order for the Company to: (i) amend or change the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of, the Series A Preferred; (ii) authorize, create or issue shares of any class of stock having rights, preferences, privileges or powers superior to the Series A Preferred; (iii) reclassify any outstanding shares into shares having rights, preferences, privileges or powers superior to the Series A Preferred; or (iv) amend the Company’s Articles of Incorporation or Bylaws in a manner that adversely affects the rights of the Series A Preferred. ● Pursuant to the Securities Purchase Agreements, holders of Series A Preferred are entitled to unlimited “piggyback” registration rights on registrations by the Company, subject to pro rata cutback at any underwriter’s discretion. Series C Preferred The Series C Preferred stock was designated on July 20, 2022. The principal feature of the Series C Preferred is that it provides the holder thereof, so long as he or she is an executive officer of the Company, with the ability to vote with the holders of the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred. 0.10 On July 25, 2022, the Company entered into a Securities Purchase Agreement with Todd Denkin, the Company’s President, pursuant to which Mr. Denkin purchased 1,000 0.10 360,200 On March 2, 2023, the Company entered into a Preferred Stock Repurchase Agreement with Todd Denkin, the Company’s president, pursuant to which Mr. Denkin surrendered his Series C Preferred back to the Company for the purchase price of $ 100 Common Stock The common stock has a par value of $ 0.001 250,000,000 123,046,825 Common Stock Transactions for the Year Ended September 30, 2024 During the year ended September 30, 2024, the Company issued 4,000,000 40,000 During the year ended September 30, 2024, the Company issued 31,950,005 6,000,000 732,595 112,200 Common Stock Transactions for the Year Ended September 30, 2023 During the year ended September 30, 2023, the Company issued 7,150,000 71,745 During the year ended September 30, 2023, the Company granted 3,400,000 1,400,000 24,820 9,860

Mezzanine Equity

Mezzanine Equity	12 Months Ended
	Sep. 30, 2024
Mezzanine Equity
Mezzanine Equity	Note 10 – Mezzanine Equity Series B Preferred The shares of Series B Preferred were designated on December 29, 2021. Each share of Series B Preferred has a Stated Value of $ 1.00 0.04 333,600 8,340,000 No holder is permitted to convert its shares of Series B Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice. Additional terms of the Series B Preferred include the following: ● The shares of Series B Preferred are not entitled to dividends, provided that if dividends are paid on the shares of common stock of the Company, the Series B Preferred will be entitled to dividends based on the number shares of common stock which the Series B Preferred may then be converted. ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock and the Series A Preferred, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends. ● Each share of Series B Preferred carries a number of votes equal to the number of shares of common stock into which such Series B Preferred may then be converted. Due to the change in control provision of the Series B Preferred, the Series B Preferred is classified as temporary equity on the balance sheet.

Common Stock Options

Common Stock Options	12 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Common Stock Options	Note 11 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012, and terminated on March 5, 2022. As amended, the 2012 Plan provides for the issuance of up to 11,500,000 Common Stock Option Issuances There were no During the year ended September 30, 2023, the Company issued to certain employees, options to purchase 2,100,000 10,446 184 0.00497 0.0056 5.75 Amortization of Stock-Based Compensation A total of $ 1,153 24,474 0 The following is a summary of information about the stock options outstanding at September 30, 2024. Summary of Common Stock Options Outstanding Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.0056 0.13 8,120,000 4.02 $ 0.052 8,120,000 $ 0.052 The fair value of each option grant is estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Weighted-Average Assumptions Used for Grants September 30, September 30, 2024 2023 Average risk-free interest rates - % 3.88 % Average expected life (in years) - 2.9 Volatility - % 184.34 % The Black-Scholes Option Pricing Model was developed for use in estimating the fair value of short-term traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including expected stock price volatility. Because the Company’s common stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion the existing models do not necessarily provide a reliable single measure of the fair value of its common stock options. During the years ended September 30, 2023, there were no options granted with an exercise price below the fair value of the underlying stock at the grant date. The weighted average fair value of options granted with exercise prices at the current fair value of the underlying stock during the year ended September 30, 2023 was approximately $ 0.005 The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Number Weighted Average of Shares Exercise Price Balance, September 30, 2022 6,020,000 $ 0.08 Options issued 2,100,000 0.006 Options repurchased/expired - - Balance, September 30, 2023 8,120,000 $ 0.069 Options issued - - Options forfeited - - Balance, September 30, 2024 8,120,000 $ 0.052 Exercisable, September 30, 2024 8,120,000 $ 0.052 As of September 30, 2024, these options in the aggregate had $ 54,330 0.029

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Sep. 30, 2024
Common Stock Warrants
Common Stock Warrants	Note 12 – Common Stock Warrants Warrants to purchase a total of 15,387,050 There were no During the year ended September 30, 2023, warrants to purchase an aggregate total of 13,887,050 0.007 The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2024 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.0074 0.10 15,387,050 7.76 $ 0.016 15,387,050 $ 0.016 The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions used for grants under the fixed option plan: The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Number Weighted Average of Shares Exercise Price Balance, September 30, 2022 2,535,001 $ 0.10 Warrants granted 13,887,050 0.007 Warrants expired - - Balance, September 30, 2023 15,387,050 $ 0.10 Warrants granted - - Warrants expired - - Balance, September 30, 2024 15,387,050 $ 0.016 Exercisable, September 30, 2024 15,387,050 $ 0.016 As of September 30, 2024, these warrants in the aggregate had $ 298,572 0.029

Leases

Leases	12 Months Ended
	Sep. 30, 2024
Lessee Disclosure [Abstract]
Leases	Note 13 – Leases On May 6, 2024, the Company entered into a lease to lease its operating and office facility under a non-cancelable real property lease agreement that expires on May 31, 2026 The components of lease expense were as follows: Schedule of Lease Expense For the For the Year Ended Year Ended September 30, September 30, 2024 2023 Operating lease cost $ 20,236 $ - Total net lease cost $ 20,236 $ - Supplemental balance sheet information related to leases was as follows: Schedule of Operating Lease Supplemental Balance Sheets September 30, September 30, 2024 2023 Operating leases: Operating lease assets $ 57,006 $ - Current portion of operating lease liabilities 36,428 $ - Noncurrent operating lease liabilities 26,838 - Total operating lease liabilities $ 63,266 $ - Weighted average remaining lease term: Operating leases 1.75 - Weighted average discount rate: Operating leases 7.9 % - % Supplemental cash flow and other information related to leases was as follows: Schedule of Operating Lease Supplemental Cash Flow For the For the Year Ended Year Ended September 30, September 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used for operating leases $ 11,309 $ - Financing cash flows used for finance leases $ - $ - Leased assets obtained in exchange for lease liabilities: Total operating lease liabilities $ 74,575 $ - Total finance lease liabilities $ - $ - The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities on a fiscal year basis, including common area maintenance fees, under non-cancelable operating leases as of September 30, 2024: Schedule of Future Minimum Operating Lease Payments Fiscal Year Ending Minimum Lease September 30, Commitments 2025 $ 40,143 2026 27,639 2027 - 2028 - 2029 - Total future undiscounted lease payments 67,782 Less interest (4,513 ) Present value of lease payments 63,266 Less current portion 36,428 Long-term operating lease liabilities $ 26,838

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14 – Commitments and Contingencies Legal Contingencies There are no material pending legal proceedings to which we are a party or to which any of our property is subject, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Note 15 – Discontinued Operations On April 20, 2023, the Company, and Digipath Labs entered into the Purchase Agreement with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 150,000 The Purchase Agreement includes a number of representations, warrantees, covenants and conditions to closing customary for this type of transaction. In addition, the closing of the transaction was subject to the approval of the Nevada Cannabis Compliance Board (the “CCB”). In the event CCB approval was not obtained by June 30, 2024, or any other condition to closing had not been satisfied by such date, either party could terminate the Purchase Agreement. Pursuant to the Purchase Agreement, the Buyer deposited $ 230,000 In connection with the transactions contemplated by the Purchase Agreement, Digipath, Digipath Labs and Buyer entered into a Management Services Agreement (the “Management Services Agreement”), dated as of April 30, 2023, pursuant to which Buyer was engaged to manage the operation of Digipath Labs’ cannabis testing laboratory (the “Lab”). The effectiveness of the Management Services Agreement was subject to the approval of the CCB, which was obtained on October 17, 2023. Pursuant to the Management Services Agreement, after the payment of expenses to third parties and a payment of 15% of cash collections to Digipath (but not less than $15,000) in each month, Buyer is entitled to a management fee of $10,000 per month. Any remaining cash generated from the operation of the Lab in any month is payable 45% to the Buyer and 55% to the Company. On February 20, 2024, we completed the sale of the net assets of our subsidiary Digipath Labs to Buyer. On June 24, 2024, the Company and the Buyer settled the final amount owed on the working capital adjustment for an additional payment of $ 42,835 1,581,981 241,419 The balance sheets of Digipath Labs are summarized below: Schedule of Discontinued Operations of Income Statement and Balance Sheet Disclosures September 30, 2024 September 30, 2023 Current assets: Accounts receivable, net $ - $ 447,410 Deposits - 18,675 Other current assets - 20,137 Total current assets - 486,222 Right-of-use asset - 274,985 Fixed assets, net - 368,681 Total long term assets - 643,666 Total Assets $ - $ 1,129,888 Current liabilities: Accounts payable $ - $ 158,869 Accrued expenses - 61,512 Current portion of operating lease liabilities - 83,757 Current maturities of notes payable - 64,517 Total current liabilities - 368,655 Operating lease liabilities - 143,245 Notes payable - 15,911 Total long term liabilities - 159,156 Total Liabilities $ - $ 527,811 The statements of operations of Digipath Labs combined are summarized below: 2024 2023 For the Years Ended September 30, 2024 2023 Revenues $ 1,635,299 $ 3,330,704 Cost of sales 650,524 1,736,401 Gross profit 984,775 1,594,303 Operating expenses: General and administrative 393,168 883,781 Professional fees 4,750 98,352 Total operating expenses 397,918 982,133 Operating income(loss) 586,857 612,170 Other income (expense): Other income - 322,798 Interest expense (1,701 ) (6,539 ) Total other income (expense) (1,701 316,259 ) Net income (loss) $ 585,156 $ 928,429

Income Tax

Income Tax	12 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Tax	Note 16 - Income Tax The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. At September 30, 2024, the Company had approximately $ 13,825,000 2032 The effective income tax rate for the years ended September 30, 2024 and 2023 consisted of the following: Schedule of Effective Income Tax Rate 2024 2023 September 30, 2024 2023 Federal statutory income tax rate 21 % 21 % State income taxes - % - % Other (2 )% - % Change in valuation allowance (18 )% (21 )% Net effective income tax rate 1 % - % The components of the Company’s deferred tax asset are as follows: Schedule of Deferred Tax Asset 2024 2023 September 30, 2024 2023 Deferred tax assets: Net operating loss carry forwards $ 2,903,300 $ 2,960,100 Net deferred tax assets before valuation allowance $ 2,903,300 $ 2,960,100 Less: Valuation allowance (2,903,300 ) (2,960,100 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at September 30, 2024 and 2023, respectively. In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 17 – Subsequent Events On October 15, 2024, the Company entered into a secured credit facility with and unrelated third party. Under the facility, the Company is able to borrow up to $ 200,000 12 February 28, 2025 20,000 On November 15, 2024, the Company issued 3,000,000 57,000 On November 27 th 200,000 On December 10, 2024, the Company entered into a Securities Purchase Agreement with A. Stone Douglass (the “Douglass Purchase Agreement”), the Company’s Chairman, President, Chief Executive Officer, Chief Financial Officer, Secretary and Director, pursuant to which Mr. Douglass purchased 1,000 0.10 On December 10, 2024, our board of directors (i) approved the Douglass Purchase Agreement, and (ii) approved and submitted for a vote of the holder of a majority of the outstanding voting stock of the Company an amendment to the Company’s Articles of Incorporation, as amended, to increase (1) the authorized shares of the Company’s common stock from 250,000,000 shares to 880,000,000 shares, and (2) the authorized shares of the Company’s preferred stock from 10,000,000 shares to 70,000,000 shares (the “Charter Amendment”). On December 10, 2024, A. Stone Douglass, as the holder of a majority of the outstanding voting stock of the Company, approved the Charter Amendment. The increase in authorized shares of the Company’s common stock and preferred stock set forth in the Charter Amendment will only take effect if and when the Company files the Charter Amendment with the Secretary of State of the State of Nevada. The Charter Amendment was filed on January 13, 2025. On December 18, 2024, the Company issued 500,000 10,000

Nature of Business and Signif_2

Nature of Business and Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Nature of Business	Nature of Business Hypha Labs, Inc. (formerly Digipath, Inc.) was incorporated in Nevada on October 5, 2010. Until February 20, 2024, Hypha Labs, Inc. and its subsidiaries (“Hypha,” the “Company,” “we,” “our” or “us”) was a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supported the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission was to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients knew exactly what was in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Hypha Labs had been operating a cannabis-testing lab in Nevada since 2015. On February 20, 2024, we completed the sale of the net assets of our subsidiary Digipath Labs, Inc. (“Digipath Labs”). As of that date we were no longer in business as a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, which supported the cannabis industry’s best practices for reliable testing, cannabis education and training. Effective March 12, 2024, the Company amended Article 1 of its Articles of Incorporation to change its name from Digipath, Inc. to Hypha Labs, Inc. Hypha Products, Inc., a wholly owned subsidiary of the Company, was formed on April 18, 2024.
Basis of Accounting	Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2024: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Hypha Labs, Inc.(formerly Digipath, Inc.) (1) Nevada Parent Hypha Products, Inc. Nevada Subsidiary Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc. (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Hypha Labs, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Hypha” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers were within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for a fair presentation of the information contained therein.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Segment Reporting	Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Accounts Receivable	Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $ 0 154,179 Assets held for sale – current
Notes Receivable	Notes Receivable Notes receivable are reported in our consolidated balance sheets at the outstanding principal balance, plus costs incurred to originate the loans, net of any unamortized premiums or discounts on purchased loans. We use the effective interest rate method to recognize finance income, which produces a constant periodic rate of return on the investment. Unearned income, discounts and premiums are amortized to finance income in our consolidated statements of operations using the effective interest rate method. Interest receivable related to the unpaid principal is recorded together with the outstanding balance in our consolidated balance sheets. Upon the prepayment of a note receivable, any prepayment penalties and unamortized loan origination, closing and commitment fees are recorded as part of finance income in our consolidated statements of operations. Notes receivable are periodically evaluated for collectability based on past credit history with note holders and their current financial condition. The Company had an allowance for credit losses of $ 670,000 720,000
Fixed Assets	Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Schedule of Estimated Useful Lives of Property, Plant and Equipment Software 3 Office equipment 5 Furniture and fixtures 5 Lab equipment 7 Leasehold improvements Term of lease Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations. As of September 30, 2024, all fixed assets balances are classified as Assets held for sale – long term
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. Our intellectual property is comprised of indefinite-lived brand names acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606 - Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue was primarily generated through our subsidiary, Digipath Labs, which recognized revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests, basis. Revenue from the performance of those services was recognized upon completion of the tests, at which time test results were delivered to the customer, provided collectability of the fee is reasonably assured. We typically required payment within thirty days of the delivery of results. During the years ended September 30, 2024 and 2023, all revenues are classified as part of Net income from discontinued operations
Discontinued Operations	Discontinued Operations On April 20, 2023, the Company and Digipath Labs entered into an Asset Purchase Agreement (the “Purchase Agreement”) with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 Assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities of discontinued operations in the Consolidated Balance Sheets as of September 30, 2024 and 2023. The results of discontinued operations are aggregated and presented separately in the Consolidated Statements of Operations as net income from discontinued operations for the years ended September 30, 2024 and 2023. The cash flows of the discontinued operations are reflected as cash flows of discontinued operations within the Company’s Consolidated Statements of Cash Flows for the years ended September 30, 2024 and 2023. Amounts presented in discontinued operations have been derived from our consolidated financial statements and accounting records using the historical basis of assets, liabilities, results of operations, and cash flows of Digipath Labs. The discontinued operations exclude general corporate allocations.
Advertising Costs	Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $ 22,205 4,444
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2024 and 2023, potential dilutive securities of 104,490,131 83,125,488 8,120,000 15,387,050 13,579,710
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not.
Uncertain Tax Positions	Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07 Segment Reporting ( Topic 280 Improvements to Reportable Segment Disclosures, In December 2023, the FASB issued ASU 2023-09 Income Taxes ( Topic 740 Improvements to Income Tax Disclosures,

Nature of Business and Signif_3

Nature of Business and Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2024: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Hypha Labs, Inc.(formerly Digipath, Inc.) (1) Nevada Parent Hypha Products, Inc. Nevada Subsidiary Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc. (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Hypha Labs, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020.
Schedule of Estimated Useful Lives of Property, Plant and Equipment	Schedule of Estimated Useful Lives of Property, Plant and Equipment Software 3 Office equipment 5 Furniture and fixtures 5 Lab equipment 7 Leasehold improvements Term of lease

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2024 and 2023, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2024 Level 1 Level 2 Level 3 Liabilities Notes payable $ - $ - $ - Convertible notes payable, net of discounts of $ 43,051 - - 1,078,235 Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2023 Level 1 Level 2 Level 3 Liabilities Notes payable $ - $ 565,000 $ - Convertible notes payable, net of discounts of $ 84,767 - - 1,725,184 Convertible notes payable - - 1,725,184

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at September 30, 2024 and 2023: Schedule of Fixed Assets 2024 2023 As of September 30, September 30, 2024 2023 Lab equipment $ 27,655 $ - Less: accumulated depreciation (1,046 ) - Total $ 26,609 $ -

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consists of the following at September 30, 2024 and 2023, respectively: Schedule of Notes Payable September 30, September 30, On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 125,000 $ - $ 565,000 Total notes payable - 565,000 Less: current maturities - (565,000 ) Notes payable $ - $ - The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 36,614 79,800 Notes payable – discontinued operations On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five December 26, 2024 $ - $ 80,428

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Related Party Convertible Notes Payable	Related party convertible notes payable consist of the following at September 30, 2024 and 2023, respectively: Schedule of Related Party Convertible Notes Payable September 30, September 30, 2024 2023 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 4,550,000 43,788 As a result of the shares issued upon the extension agreement, the lender now holds more the 5% of the total outstanding common shares, and is therefore considered a related party. On February 27, 2024, the Company repaid the note and related accrued interest in full. $ - $ 350,000 Total related party convertible notes payable - 350,000 Less: unamortized debt discounts - (10,748 ) Total convertible debt - 339,252 Less: current maturities - - Related party convertible notes payable $ - $ 339,252
Schedule of Convertible Notes Payable	Convertible notes payable consist of the following at September 30, 2024 and 2023, respectively: Schedule of Convertible Notes Payable September 30, September 30, 2024 2023 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $ 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 1,950,000 20,968 - 150,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 August 10, 2022 0.03 90,000 3,000,000 0.03 355,469 98,188 February 11, 2024 4,621,105 32,166 355,469 355,469 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 August 10, 2022 0.03 February 11, 2024 4,550,000 31,671 40,000 February 11, 2025 0.01 474,539 310,000 350,000 On October 1, 2022, the Company entered into a senior secured convertible note that carries an 8 February 11, 2024 362,765 0.01 4,715,945 30,102 362,765 362,765 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 August 10, 2022 0.03 - 150,000 Total convertible notes payable 1,078,235 1,418,234 Less: unamortized debt discounts - (32,302 ) Total convertible debt 1,078,235 1,385,932 Less: current maturities (1,078,235 ) (1,385,932 ) Convertible notes payable $ - $ -
Schedule of Interest Expense	The Company recognized interest expense for the years ended September 30, 2024 and 2023, respectively, as follows: Schedule of Interest Expense September 30, September 30, Interest on notes payable $ 36,614 $ 79,800 Amortization of debt discounts 43,050 135,655 Interest on convertible notes 89,603 148,812 Total interest expense $ 169,267 $ 364,267

Common Stock Options (Tables)

Common Stock Options (Tables)	12 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Common Stock Options Outstanding	The following is a summary of information about the stock options outstanding at September 30, 2024. Summary of Common Stock Options Outstanding Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.0056 0.13 8,120,000 4.02 $ 0.052 8,120,000 $ 0.052
Schedule of Weighted-Average Assumptions Used for Grants	The fair value of each option grant is estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Weighted-Average Assumptions Used for Grants September 30, September 30, 2024 2023 Average risk-free interest rates - % 3.88 % Average expected life (in years) - 2.9 Volatility - % 184.34 %
Schedule of Activity of Outstanding Common Stock Options	The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Number Weighted Average of Shares Exercise Price Balance, September 30, 2022 6,020,000 $ 0.08 Options issued 2,100,000 0.006 Options repurchased/expired - - Balance, September 30, 2023 8,120,000 $ 0.069 Options issued - - Options forfeited - - Balance, September 30, 2024 8,120,000 $ 0.052 Exercisable, September 30, 2024 8,120,000 $ 0.052

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
	Sep. 30, 2024
Common Stock Warrants
Summary of Common Stock Warrants Outstanding	The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2024 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.0074 0.10 15,387,050 7.76 $ 0.016 15,387,050 $ 0.016
Schedule of Outstanding Common Stock Warrants Activity	The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Number Weighted Average of Shares Exercise Price Balance, September 30, 2022 2,535,001 $ 0.10 Warrants granted 13,887,050 0.007 Warrants expired - - Balance, September 30, 2023 15,387,050 $ 0.10 Warrants granted - - Warrants expired - - Balance, September 30, 2024 15,387,050 $ 0.016 Exercisable, September 30, 2024 15,387,050 $ 0.016

Leases (Tables)

Leases (Tables)	12 Months Ended
	Sep. 30, 2024
Lessee Disclosure [Abstract]
Schedule of Lease Expense	The components of lease expense were as follows: Schedule of Lease Expense For the For the Year Ended Year Ended September 30, September 30, 2024 2023 Operating lease cost $ 20,236 $ - Total net lease cost $ 20,236 $ -
Schedule of Operating Lease Supplemental Balance Sheets	Supplemental balance sheet information related to leases was as follows: Schedule of Operating Lease Supplemental Balance Sheets September 30, September 30, 2024 2023 Operating leases: Operating lease assets $ 57,006 $ - Current portion of operating lease liabilities 36,428 $ - Noncurrent operating lease liabilities 26,838 - Total operating lease liabilities $ 63,266 $ - Weighted average remaining lease term: Operating leases 1.75 - Weighted average discount rate: Operating leases 7.9 % - %
Schedule of Operating Lease Supplemental Cash Flow	Supplemental cash flow and other information related to leases was as follows: Schedule of Operating Lease Supplemental Cash Flow For the For the Year Ended Year Ended September 30, September 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used for operating leases $ 11,309 $ - Financing cash flows used for finance leases $ - $ - Leased assets obtained in exchange for lease liabilities: Total operating lease liabilities $ 74,575 $ - Total finance lease liabilities $ - $ -
Schedule of Future Minimum Operating Lease Payments	The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities on a fiscal year basis, including common area maintenance fees, under non-cancelable operating leases as of September 30, 2024: Schedule of Future Minimum Operating Lease Payments Fiscal Year Ending Minimum Lease September 30, Commitments 2025 $ 40,143 2026 27,639 2027 - 2028 - 2029 - Total future undiscounted lease payments 67,782 Less interest (4,513 ) Present value of lease payments 63,266 Less current portion 36,428 Long-term operating lease liabilities $ 26,838

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations of Income Statement and Balance Sheet Disclosures	The balance sheets of Digipath Labs are summarized below: Schedule of Discontinued Operations of Income Statement and Balance Sheet Disclosures September 30, 2024 September 30, 2023 Current assets: Accounts receivable, net $ - $ 447,410 Deposits - 18,675 Other current assets - 20,137 Total current assets - 486,222 Right-of-use asset - 274,985 Fixed assets, net - 368,681 Total long term assets - 643,666 Total Assets $ - $ 1,129,888 Current liabilities: Accounts payable $ - $ 158,869 Accrued expenses - 61,512 Current portion of operating lease liabilities - 83,757 Current maturities of notes payable - 64,517 Total current liabilities - 368,655 Operating lease liabilities - 143,245 Notes payable - 15,911 Total long term liabilities - 159,156 Total Liabilities $ - $ 527,811 The statements of operations of Digipath Labs combined are summarized below: 2024 2023 For the Years Ended September 30, 2024 2023 Revenues $ 1,635,299 $ 3,330,704 Cost of sales 650,524 1,736,401 Gross profit 984,775 1,594,303 Operating expenses: General and administrative 393,168 883,781 Professional fees 4,750 98,352 Total operating expenses 397,918 982,133 Operating income(loss) 586,857 612,170 Other income (expense): Other income - 322,798 Interest expense (1,701 ) (6,539 ) Total other income (expense) (1,701 316,259 ) Net income (loss) $ 585,156 $ 928,429

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate	The effective income tax rate for the years ended September 30, 2024 and 2023 consisted of the following: Schedule of Effective Income Tax Rate 2024 2023 September 30, 2024 2023 Federal statutory income tax rate 21 % 21 % State income taxes - % - % Other (2 )% - % Change in valuation allowance (18 )% (21 )% Net effective income tax rate 1 % - %
Schedule of Deferred Tax Asset	The components of the Company’s deferred tax asset are as follows: Schedule of Deferred Tax Asset 2024 2023 September 30, 2024 2023 Deferred tax assets: Net operating loss carry forwards $ 2,903,300 $ 2,960,100 Net deferred tax assets before valuation allowance $ 2,903,300 $ 2,960,100 Less: Valuation allowance (2,903,300 ) (2,960,100 ) Net deferred tax assets $ - $ -

Schedule of Entities Under Comm

Schedule of Entities Under Common Control and Ownership (Details)	12 Months Ended
	Sep. 30, 2024
Entities Under Common Control and Ownership One [Member]
Name of Entity	Hypha Labs, Inc.(formerly Digipath, Inc.)	[1]
Jurisdiction of Incorporation	Nevada	[1]
Relationship	Parent	[1]
Entities Under Common Control and Ownership Two [Member]
Name of Entity	Hypha Products, Inc.
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Entities Under Common Control and Ownership Three [Member]
Name of Entity	Digipath Labs, Inc.
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Entities Under Common Control and Ownership Four [Member]
Name of Entity	Digipath Labs CA, Inc.	[2]
Jurisdiction of Incorporation	California	[2]
Relationship	Subsidiary	[2]
Entities Under Common Control and Ownership Five [Member]
Name of Entity	Digipath Labs S.A.S.	[3]
Jurisdiction of Incorporation	Colombia	[3]
Relationship	Subsidiary	[3]
Entities Under Common Control And Ownership Six [Member]
Name of Entity	VSSL Enterprises, Ltd.	[4]
Jurisdiction of Incorporation	Canada	[4]
Relationship	Subsidiary	[4]
[1]Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Hypha Labs, Inc., the parent company.[2]Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations.[3]Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations.[4]Acquired on March 11, 2020.

Schedule of Estimated Useful Li

Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)	Sep. 30, 2024
Computer Software, Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]	Useful Life, Lease Term [Member]

Nature of Business and Signif_4

Nature of Business and Significant Accounting Policies (Details Narrative)		12 Months Ended
	Apr. 20, 2023 USD ($)	Sep. 30, 2024 USD ($) Segment shares	Sep. 30, 2023 USD ($) shares
Schedule of Equity Method Investments [Line Items]
Number of operating segment | Segment		1
Allowance for doubtful accounts | $		$ 0	$ 154,179
Allowance for credit losses | $		670,000	720,000
Cash purchase price | $			275,000
Advertising expense | $		$ 22,205	$ 4,444
Antidilutive securities earning per share		104,490,131	83,125,488
Conversion of preferred shares		8,340,000
Series A Convertible Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Conversion of preferred shares		13,579,710	13,579,710
Series B Convertible Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Conversion of preferred shares		13,579,710	13,579,710
Share-Based Payment Arrangement, Option [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive securities earning per share		8,120,000	8,120,000
Warrant [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive securities earning per share		15,387,050	15,387,050
Discontinued Operations, Held-for-Sale [Member] | Purchase Agreement [Member]
Schedule of Equity Method Investments [Line Items]
Cash purchase price | $	$ 2,300,000

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 20,547,426	$ 19,761,997

Summary of Financial Instrument

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes payable
Convertible notes payable
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes payable		565,000
Convertible notes payable
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes payable
Convertible notes payable	$ 1,078,235	$ 1,725,184

Summary of Financial Instrume_2

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) (Parenthetical) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Convertible Debt [Member]
Short-Term Debt [Line Items]
Convertible notes discounts	$ 43,051	$ 84,767

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Directors [Member]
Related Party Transaction [Line Items]
Common stock granted	6,000,000	1,400,000
Director [Member]
Related Party Transaction [Line Items]
Common stock granted		1,400,000
Compensation for services	$ 112,200	$ 9,860
Officer [Member]
Related Party Transaction [Line Items]
Common stock granted		3,400,000
Compensation for services		$ 24,820
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Service for incurred fees	60,000	60,000
Board of Directors [Member]
Related Party Transaction [Line Items]
Service for incurred fees	24,000	34,000
Due to related party	10,000	$ 138,000
Officer and Directors [Member]
Related Party Transaction [Line Items]
Reimbursable expenses	$ 5,923

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) (Parenthetical) - USD ($)					12 Months Ended
	Jan. 03, 2024	Dec. 08, 2022	Sep. 10, 2021	Dec. 26, 2019	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Repayments of notes payable					$ 595,965	$ 100,000
Canna Lab Note [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, maturity date			Sep. 10, 2024
Additional debt amount			$ 675,000
Debt instrument stated percentage			12%
Debt instrument periodic payment			$ 22,419.66
Secured Promissory Note [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional debt amount							$ 115,000
Repayments of notes payable							$ 125,000
Note Payable [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Interest expense					$ 36,614	$ 79,800
Note Payable [Member] | Discontinued Operations [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, maturity date				Dec. 26, 2024
Debt instrument stated percentage				5.75%
Debt instrument periodic payment				$ 5,622
Payments for lab equipment				377,124
Proceeds from bank loan				$ 291,931
Debt instrument term description				5 years
Asset Purchase Agreement [Member] | Invictus Wealth Group [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, maturity date	Dec. 31, 2025	Dec. 31, 2023
Debt instrument stated percentage		10%

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)

Dec. 31, 2025

Sep. 30, 2025

Jun. 30, 2025

Mar. 31, 2025

Jan. 13, 2025

Dec. 31, 2024

Sep. 30, 2024

Jun. 30, 2024

Mar. 31, 2024

Jan. 03, 2024

Dec. 31, 2023

Sep. 30, 2023

Jun. 30, 2023

Dec. 08, 2022

Jun. 13, 2019

Financing Receivable, Modified [Line Items]

Purchase price note receivable

Asset Purchase Agreement [Member] | Invictus Wealth Group [Member]

Financing Receivable, Modified [Line Items]

Debt instrument stated percentage

10%

Purchase price note receivable

$ 900,000

Upfront payment

275,000

Purchase price note receivable

$ 625,000

Debt instrument maturity date

Dec. 31, 2025

Dec. 31, 2023

Debt final payment

$ 425,000

100,000

$ 100,000

Received portion of upfront payment

$ 275,000

Debt final payment

$ 74,000

Asset Purchase Agreement [Member] | Invictus Wealth Group [Member] | Extended Maturity [Member]

Financing Receivable, Modified [Line Items]

Debt final payment

$ 50,000

$ 50,000

$ 425,000

Asset Purchase Agreement [Member] | Invictus Wealth Group [Member] | Extended Maturity [Member] | Forecast [Member]

Financing Receivable, Modified [Line Items]

Debt final payment

$ 216,780

$ 125,000

$ 100,000

$ 100,000

Asset Purchase Agreement [Member] | Invictus Wealth Group [Member] | Extended Maturity [Member] | Subsequent Event [Member]

Financing Receivable, Modified [Line Items]

Debt final payment

$ 50,000

Northwest Analytical Labs, Inc. [Member]

Financing Receivable, Modified [Line Items]

Loan received from related party

$ 95,000

Debt instrument stated percentage

10%

Invictus Wealth Group [Member] | Asset Purchase Agreement [Member] | Extended Maturity [Member]

Financing Receivable, Modified [Line Items]

Debt final payment

$ 100,000

$ 100,000

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Lab equipment	$ 27,655
Less: accumulated depreciation	(1,046)
Total	$ 26,609

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Impairment expense		$ 55,000

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Short-Term Debt [Line Items]
Total notes payable		$ 565,000
Less: current maturities		(565,000)
Notes payable
Notes Payable [Member]
Short-Term Debt [Line Items]
Total notes payable		$ 565,000

Schedule of Related Party Conve

Schedule of Related Party Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Short-Term Debt [Line Items]
Total related party convertible notes payable	$ 1,078,235	$ 1,418,234
Total convertible debt	1,078,235	1,385,932
Less: current maturities	(1,078,235)	(1,385,932)
Related Party [Member]
Short-Term Debt [Line Items]
Total related party convertible notes payable		350,000
Less: unamortized debt discounts		(10,748)
Total convertible debt		339,252
Less: current maturities
Related party convertible notes payable		339,252
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Less: unamortized debt discounts	0
Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Total related party convertible notes payable		$ 350,000

Schedule of Related Party Con_2

Schedule of Related Party Convertible Notes Payable (Details) (Parenthetical) - Secured Subordinated Convertible Promissory Note [Member] - Accredited Investors [Member] - USD ($)	Aug. 08, 2022	Dec. 29, 2020	Dec. 28, 2020	Feb. 10, 2020
Short-Term Debt [Line Items]
Principal amount		$ 50,000	$ 400,000	$ 350,000
Maturity date	Feb. 11, 2024			Aug. 10, 2022
Debt instrument interest percentage				9%
Conversion price		$ 0.03	$ 0.03	$ 0.15
Proceeds from convertible debt			$ 50,000
Debt converted principal value, shares		1,666,667
Shares of common stock issued	4,550,000
Debt instrument fair value	$ 43,788
Debt instrument agreement	As a result of the shares issued upon the extension agreement, the lender now holds more the 5% of the total outstanding common shares, and is therefore considered a related party. On February 27, 2024, the Company repaid the note and related accrued interest in full.

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Short-Term Debt [Line Items]
Total convertible notes payable	$ 1,078,235	$ 1,418,234
Less: unamortized debt discounts		(32,302)
Total convertible debt	1,078,235	1,385,932
Less: current maturities	(1,078,235)	(1,385,932)
Nonrelated Party [Member]
Short-Term Debt [Line Items]
Convertible notes payable
Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	50,000	50,000
Convertible Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total convertible notes payable		150,000
Convertible Notes Payable Three [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	355,469	355,469
Convertible Notes Payable Four [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	310,000	350,000
Convertible Notes Payable Five [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	362,765	362,765
Convertible Notes Payable Six [Member]
Short-Term Debt [Line Items]
Total convertible notes payable		$ 150,000

Schedule of Convertible Notes_2

Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)

12 Months Ended

Jan. 29, 2024

Jan. 22, 2024

Oct. 02, 2022

Aug. 08, 2022

Sep. 30, 2021

Feb. 22, 2021

Dec. 29, 2020

Dec. 28, 2020

Sep. 30, 2020

Feb. 11, 2020

Sep. 23, 2019

Nov. 08, 2018

Nov. 05, 2018

Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2022

Short-Term Debt [Line Items]

Amortization of debt discount premium

$ 43,050

$ 135,655

Loss on debt extinguishment

$ (956,494)

9% Secured Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Principal amount

$ 10,000

$ 60,000

$ 50,000

Maturity date

Feb. 11, 2024

Aug. 11, 2022

Debt instrument interest percentage

9%

Conversion price

$ 0.03

$ 0.03

$ 0.15

Proceeds from convertible debt

$ 10,000

Debt converted principal value, shares

333,334

Shares issued in exchange of extension

650,000

Debt instrument fair value

$ 6,989

9% Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Principal amount

$ 200,000

$ 150,000

Maturity date

Feb. 11, 2024

Aug. 11, 2022

Debt instrument interest percentage

9%

Conversion price

$ 0.03

$ 0.03

$ 0.15

Proceeds from convertible debt

$ 50,000

Debt converted principal value, shares

1,666,667

Debt converted principal amount

$ 50,000

9% Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors One [Member]

Short-Term Debt [Line Items]

Shares issued in exchange of extension

1,950,000

Debt instrument fair value

$ 20,968

Senior Secured Convertible Note [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2024

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.03

$ 0.03

$ 0.11

Proceeds from convertible debt

$ 200,000

Debt converted principal value, shares

3,000,000

Debt converted principal amount

$ 90,000

Debt instrument periodic payment

$ 355,469

Amortization of debt discount premium

$ 98,188

Debt instrument purchase of warrant

4,621,105

Debt instrument fair value of warrant

$ 32,166

Senior Secured Convertible Note One [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2025

Feb. 11, 2024

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.01

$ 0.03

$ 0.14

Proceeds from convertible debt

$ 350,000

Debt instrument purchase of warrant

4,550,000

Debt instrument fair value of warrant

$ 31,671

Conversion of notes payable into common stock value

$ 40,000

Loss on debt extinguishment

$ 474,539

Senior Secured Convertible Note Two [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2024

Debt instrument interest percentage

8%

Conversion price

$ 0.01

Debt instrument purchase of warrant

4,715,945

Debt instrument fair value of warrant

$ 30,102

Debt conversion original debt amount

$ 362,765

Senior Secured Convertible Note Three [Member]

Short-Term Debt [Line Items]

Maturity date

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.03

$ 0.14

Proceeds from convertible debt

$ 150,000

Schedule of Interest Expense (D

Schedule of Interest Expense (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Debt Disclosure [Abstract]
Interest on notes payable	$ 36,614	$ 79,800
Amortization of debt discounts	43,050	135,655
Interest on convertible notes	89,603	148,812
Total interest expense	$ 169,267	$ 364,267

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Short-Term Debt [Line Items]
Amortization of Debt Discount (Premium)	$ 43,050	$ 135,655
Maximum Share Amount [Member]
Short-Term Debt [Line Items]
Maximum amount owned percentage of issued and outstanding common shares	4.99%
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Amortization of Debt Discount (Premium)	$ 43,050	135,655
Debt Instrument, Unamortized Discount	0
Convertible notes interest expense	$ 89,603	$ 148,812

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)			12 Months Ended
	Mar. 02, 2023	Jul. 25, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Class of Stock [Line Items]
Preferred stock, shares authorized			70,000,000
Preferred stock, par value			$ 0.001
Stock repurchased, value				$ 100
Common stock, par value			$ 0.001	$ 0.001
Common stock, shares authorized			250,000,000	250,000,000
Common stock, shares issued			123,046,825	87,096,820
Common stock, shares outstanding			123,046,825	87,096,820
Issuance of common shares to settle stock payable
Director [Member]
Class of Stock [Line Items]
Common stock granted				1,400,000
Compensation for services			$ 112,200	$ 9,860
Officer [Member]
Class of Stock [Line Items]
Common stock granted				3,400,000
Compensation for services				$ 24,820
Common Stock [Member]
Class of Stock [Line Items]
Stock repurchased, value
Issuance of common shares to settle stock payable, shares			4,000,000	7,150,000
Issuance of common shares to settle stock payable			$ 40,000	$ 7,150
Shares of stock-based compensation			31,950,005
Stock issuance for aggregate value			$ 732,595
Compensation for services			$ 0
Common Stock [Member] | Director [Member]
Class of Stock [Line Items]
Shares of stock-based compensation			6,000,000
Stock issued value related to directors			$ 112,200
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			6,000,000	6,000,000
Preferred stock, par value			$ 0.001	$ 0.001
Preferred stock, shares outstanding			1,047,942	1,047,942
Series A Convertible Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding					1,047,942
Stock repurchased, value
Issuance of common shares to settle stock payable
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity, shares authorized			1,500,000	1,500,000
Temporary equity, shares outstanding			333,600	333,600
Temporary equity, shares issued			333,600	333,600
Series B Convertible Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity, shares outstanding			333,600	333,600	333,600
Stock repurchased, value
Issuance of common shares to settle stock payable
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			1,000
Preferred stock, shares designated remaining			2,499,000
Preferred stock voting rights			the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred.
Preferred stock voting rights			$ 0.10
Stock repurchased, value	$ 100
Series C Preferred Stock [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Conversion of stock shares converted		1,000
Share weighted average price of shares purchased		$ 0.10
Compensation expenses to officer		$ 360,200
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			1,000	1,000
Preferred stock, par value			$ 0.001	$ 0.001
Preferred stock, shares outstanding			0	0
Series C Convertible Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity, shares outstanding					1,000
Temporary equity, shares issued					1,000
Stock repurchased, value				$ 1
Issuance of common shares to settle stock payable
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of stock shares converted			1,047,942
Convertible shares			5,239,710
Common stock, terms of conversion			No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice.
Percentage of distribution on purchase price			100%
Series A Preferred Stock [Member] | Note holders [Member]
Class of Stock [Line Items]
Percentage of equity beneficial ownership			4.99%
Series A Preferred Stock [Member] | Note Holder [Member]
Class of Stock [Line Items]
Percentage of equity beneficial ownership			4.99%
Common Stock [Member]
Class of Stock [Line Items]
Issuance of common shares to settle stock payable, shares				7,150,000
Issuance of common shares to settle stock payable				$ 71,745

Mezzanine Equity (Details Narra

Mezzanine Equity (Details Narrative)	12 Months Ended
	Sep. 30, 2024 $ / shares shares
Preferred stock, par value	$ 0.001
Conversion of stock shares issued | shares	8,340,000
Series B Preferred Stock [Member]
Preferred stock, par value	$ 1
Conversion price	$ 0.04
Conversion shares converted | shares	333,600
Common stock, terms of conversion	No holder is permitted to convert its shares of Series B Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice.
Conversion of stock description	Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock and the Series A Preferred, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends.

Summary of Common Stock Options

Summary of Common Stock Options Outstanding (Details)	12 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Range of Exercise Price, Minimum	$ 0.0056
Range of Exercise Price, Maximum	$ 0.13
Number of Options Outstanding | shares	8,120,000
Weighted Average Remaining Contractual Life	4 years 7 days
Weighted Average Exercise Price	$ 0.052
Number of Shares Exercisable | shares	8,120,000
Weighted Average Exercise Price Exercisable	$ 0.052

Schedule of Weighted-Average As

Schedule of Weighted-Average Assumptions Used for Grants (Details)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Average risk-free interest rates		3.88%
Average expected life		2 years 10 months 24 days
Volatility		184.34%

Schedule of Activity of Outstan

Schedule of Activity of Outstanding Common Stock Options (Details) - $ / shares	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Number of Shares Outstanding, Beginning balance	8,120,000	6,020,000
Weighted Average Exercise Price, Outstanding, Beginning	$ 0.069	$ 0.08
Number of Shares Options issued		2,100,000
Weighted Average Exercise Price, Options issued		$ 0.006
Number of Shares Options repurchased/expired
Weighted Average Exercise Price, Options repurchased/expired
Number of Shares Options forfeited
Weighted Average Exercise Price, Options forfeited
Number of Shares Outstanding, Ending balance	8,120,000	8,120,000
Weighted Average Exercise Price, Outstanding, Ending	$ 0.052	$ 0.069
Number of Shares Exercisable, Ending	8,120,000
Weighted Average Exercise Price, Exercisable, Ending	$ 0.052

Common Stock Options (Details N

Common Stock Options (Details Narrative) - USD ($)		12 Months Ended
	Jun. 21, 2016	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility rate			184.34%
Expected term			2 years 10 months 24 days
Weighted average fair value of options granted with exercise price			$ 0.006
Intrinsic value , outstanding		$ 54,330
Market price, per share		$ 0.029
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average fair value of options granted with exercise price			$ 0.005
Amortization of Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expenses		$ 1,153	$ 24,474
Unamortized expenses expected to be expensed		0
Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock issued during period value issued for services		$ 0
2012 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility rate			184%
Call option values price			$ 0.00497
Exercise prices			$ 0.0056
Expected term			5 years 9 months
2012 Stock Incentive Plan [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued to certain employees			2,100,000
Total fair value			$ 10,446
2012 Stock Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued under stock plan	11,500,000

Summary of Common Stock Warrant

Summary of Common Stock Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Common Stock Warrants
Exercise Price Range Lower Range	$ 0.0074
Exercise Price Range Upper Range	$ 0.10
Number of Warrants Outstanding	15,387,050	15,387,050	2,535,001
Weighted Average Remaining Contractual Life	7 years 9 months 3 days
Weighted Average Exercise Price	$ 0.016
Number of Warrants Exercisable	15,387,050
Weighted Average Exercise Price, Exercisable	$ 0.016

Schedule of Outstanding Common

Schedule of Outstanding Common Stock Warrants Activity (Details) - $ / shares	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Common Stock Warrants
Number of Shares, Balance beginning	15,387,050	2,535,001
Weighted Average Exercise Price, Balance beginning	$ 0.10	$ 0.10
Number of Shares, Warrants granted		13,887,050
Weighted Average Exercise Price, Warrants granted		$ 0.007
Number of Shares, Warrants expired
Weighted Average Exercise Price, Warrants expired
Number of Shares, Balance ending	15,387,050	15,387,050
Weighted Average Exercise Price, Balance, ending	$ 0.016	$ 0.10
Number of Shares, Exercisable	15,387,050
Weighted Average Exercise Price, Exercisable	$ 0.016

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Number of warrants outstanding	15,387,050	15,387,050	2,535,001
Number of warrant granted		13,887,050
Weighted average exercise price granted		$ 0.007
Warrant [Member]
Warrants, intrinic value	$ 298,572
Intrinsic value, market price per share	$ 0.029

Schedule of Lease Expense (Deta

Schedule of Lease Expense (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Lessee Disclosure [Abstract]
Operating lease cost	$ 20,236
Total net lease cost	$ 20,236

Schedule of Operating Lease Sup

Schedule of Operating Lease Supplemental Balance Sheets (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Operating leases:
Operating lease assets	$ 57,006
Current portion of operating lease liabilities	36,428
Noncurrent operating lease liabilities	26,838
Total operating lease liabilities	$ 63,266
Operating leases weighted average remaining lease term	1 year 9 months
Operating Lease, Weighted Average Discount Rate, Percent	7.90%

Schedule of Operating Lease S_2

Schedule of Operating Lease Supplemental Cash Flow (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Lessee Disclosure [Abstract]
Operating cash flows used for operating leases	$ 11,309
Financing cash flows used for finance leases
Total operating lease liabilities	74,575
Total finance lease liabilities

Schedule of Future Minimum Oper

Schedule of Future Minimum Operating Lease Payments (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Lessee Disclosure [Abstract]
2025	$ 40,143
2026	27,639
2027
2028
2029
Total future undiscounted lease payments	67,782
Less interest	(4,513)
Total operating lease liabilities	63,266
Less current portion	36,428
Long-term operating lease liabilities	$ 26,838

Leases (Details Narrative)

Leases (Details Narrative)	May 06, 2024
Lessee Disclosure [Abstract]
Lease expiry date	May 31, 2026

Schedule of Balance Sheet Discl

Schedule of Balance Sheet Disclosures of Discontinued Operations (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Current assets:
Accounts receivable, net		$ 447,410
Deposits		18,675
Other current assets		20,137
Total current assets		486,222
Right-of-use asset		274,985
Fixed assets, net		368,681
Total long term assets		643,666
Total Assets		1,129,888
Current liabilities:
Accounts payable		158,869
Accrued expenses		61,512
Current portion of operating lease liabilities		83,757
Current maturities of notes payable		64,517
Total current liabilities		368,655
Operating lease liabilities		143,245
Notes payable		15,911
Total long term liabilities		159,156
Total Liabilities		$ 527,811

Schedule of Income Statement fr

Schedule of Income Statement from Discontinued Operations (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Revenues	$ 1,635,299	$ 3,330,704
Cost of sales	650,524	1,736,401
Gross profit	984,775	1,594,303
Operating expenses:
General and administrative	393,168	883,781
Professional fees	4,750	98,352
Total operating expenses	397,918	982,133
Operating income(loss)	586,857	612,170
Other income (expense):
Other income		322,798
Interest expense	(1,701)	(6,539)
Total other income (expense)	(1,701)	316,259
Net income (loss)	$ 585,156	$ 928,429

Discontinued Operations (Detail

Discontinued Operations (Details Narrative) - USD ($)				12 Months Ended
	Feb. 20, 2024	Apr. 30, 2023	Apr. 20, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price					$ 275,000
Working capital adjustment	$ 42,835			241,419
Gain on sale of subsidiary net assets	$ 1,581,981			$ 1,548,998
Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Working capital			$ 150,000
Escrow deposits			230,000
Management Services Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Description of collaborative arrangement		The effectiveness of the Management Services Agreement was subject to the approval of the CCB, which was obtained on October 17, 2023. Pursuant to the Management Services Agreement, after the payment of expenses to third parties and a payment of 15% of cash collections to Digipath (but not less than $15,000) in each month, Buyer is entitled to a management fee of $10,000 per month. Any remaining cash generated from the operation of the Lab in any month is payable 45% to the Buyer and 55% to the Company.
Discontinued Operations, Held-for-Sale [Member] | Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price			$ 2,300,000

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate (Details)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Federal statutory income tax rate	21%	21%
State income taxes
Other	(2.00%)
Change in valuation allowance	(18.00%)	(21.00%)
Net effective income tax rate	1%

Schedule of Deferred Tax Asset

Schedule of Deferred Tax Asset (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 2,903,300	$ 2,960,100
Net deferred tax assets before valuation allowance	2,903,300	2,960,100
Less: Valuation allowance	(2,903,300)	(2,960,100)
Net deferred tax assets

Income Tax (Details Narrative)

Income Tax (Details Narrative)	12 Months Ended
	Sep. 30, 2024 USD ($)
Income Tax Disclosure [Abstract]
Federal net operating loss	$ 13,825,000
Expiration year	2032
Unrecognized Tax Benefits	$ 0

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)					12 Months Ended
	Dec. 18, 2024	Dec. 10, 2024	Nov. 15, 2024	Oct. 15, 2024	Sep. 30, 2024	Nov. 27, 2024
Series C Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock voting rights					the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred.
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of common stock issued for services	500,000		3,000,000
Value of common stock issued for services	$ 10,000		$ 57,000
Subsequent Event [Member] | Series C Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock voting rights		holder of a majority of the outstanding voting stock of the Company an amendment to the Company’s Articles of Incorporation, as amended, to increase (1) the authorized shares of the Company’s common stock from 250,000,000 shares to 880,000,000 shares, and (2) the authorized shares of the Company’s preferred stock from 10,000,000 shares to 70,000,000 shares (the “Charter Amendment”).
Subsequent Event [Member] | Asset Purchase Agreement [Member]
Subsequent Event [Line Items]
Escrow deposit						$ 200,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Series C Preferred Stock [Member]
Subsequent Event [Line Items]
Purchase common stock		1,000
Price per share		$ 0.10
Secured Credit Facility [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Debt instrument face amount				$ 200,000
Debt instrument stated percentage				12%
Debt instrument maturity date				Feb. 28, 2025
Interest expense				$ 20,000